Marita Pauline Feldkaemper

Dr. Marita Pauline Feldkaemper

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Experimental Eye Research
Verified
Journal Article
Closed access
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
FSFrank Schaeffel
Frank Schaeffel

4 September 2018 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
MWMin Wang
Min Wang
FSFrank Schaeffel
Frank Schaeffel
BJBing Jiang
Bing Jiang
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
Purpose: There is ample evidence that retinal dopamine (DA) is involved in the biochemical signaling cascade that controls emmetropization, but it is unknown how its release depends on the spectral composition of ambient light. We have studied DA release, refractive development, and growth in chicken eyes that were exposed to light of different spectral bands, and had either normal vision or were covered by frosted diffusers to induce myopia. Methods: Experiment 1: After spending the night in the dark, chicks were exposed to white room light (spectral range, 430–630 nm) or kept in the dark. Additional chicks were unilaterally exposed to blue (peak at 470 nm), red (620 nm), or UV lighting (375 nm) for 30 minutes and their fellow eyes covered with black occluders to minimize light exposure. Experiment 2: In the second experiment, chicks wore diffusers over one eye to induce deprivation myopia and were raised for 5 days in either white room light or in lighting supplied by UV, blue, or red light-emitting diodes (LEDs). Refractive states were recorded daily with infrared photoretinoscopy, and ocular dimensions at the start and end of the experiment with A-scan ultrasonography. DA and its metabolites were measured in retina and vitreous by high pressure liquid chromatography-electrochemical detection (HPLC-ED) in all cases. Results: Compared to chicks kept in the dark, retinal DA and vitreal 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations were clearly elevated after 30 minutes in white light. Vitreal DOPAC was also increased in red, blue, and UV lighting, compared to the fellow eyes covered with black occluders (black occluder versus blue light: 1.31 ± 0.32 vs. 1.70 ± 0.37; red: 1.26 ± 0.33 vs. 1.64 ± 0.38; UV: 1.13 ± 0.19 vs. 1.63 ± 0.21 ng/0.1 g wet weight). Chickens developed significantly less deprivation myopia, with shorter eyes, when raised under UV and blue lighting for 5 days, compared to under red and white light. Eyes with normal vision became more hyperopic in blue and UV lighting. Vitreal DOPAC levels were lowest after 5 days of exposure to UV lighting. Conclusions: Red, blue, and UV lighting all stimulated the release of retinal DA, but there were wavelength-dependent differences in DA release and metabolism. Less deprivation myopia developed in UV and blue lighting, compared to white and red light. The application of these findings to humans is limited by the fact that, different from chicks, humans have very low sensitivity in the near-UV region of the spectrum.

1 January 2009 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
INIrina Neacsu
Irina Neacsu
FSFrank Schaeffel
Frank Schaeffel
Purpose. In animal models, it has been shown that the retina can use the defocus of the projected image to control emmetropization. Glucagon may be involved in the sign of defocus detection, at least in chickens. Since glucagon and insulin often have opposite effects in metabolic pathways, the effect of insulin on eye growth was investigated.

1 November 2002 in Visual Neuroscience
Verified
Journal Article
Closed access
PDF file
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
FSFrank Schaeffel
Frank Schaeffel
Eye growth and refraction are regulated by visual processing in the retina. Until now, the messengers released by the retina to induce these changes are largely unknown. Previously, it was found that glucagon amacrine cells respond to defocus in the retinal image and even to its sign. The expression of the immediate-early gene product ZENK increased in this cell population in eyes wearing plus lenses and decreased in minus lens-treated chicks. Moreover, it was shown that the amount of retinal glucagon mRNA increased during treatment with positive lenses. Therefore, it seems likely that these cells contribute to the visual regulation of ocular growth and that glucagon may act as a stop signal for eye growth. The purpose of the present study was to accumulate further evidence for a role of glucagon in the visual control of eye growth. Chicks were treated with plus and minus lenses after injection of different amounts of the glucagon antagonist des-His1-Glu9-glucagon-amide or the agonist Lys17,18,Glu21-glucagon, respectively. Refractive development and eye growth were recorded by automated infrared photorefraction and A-scan ultrasound, respectively. The glucagon antagonist inhibited hyperopia development, albeit only in a narrow concentration range, and at most by 50%, but not myopia development. In contrast, the agonist inhibited myopia development in a dose-dependent fashion. At high concentrations, it also prevented hyperopia development.

1 February 2004 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
CBChristine Buck
Christine Buck
FSFrank Schaeffel
Frank Schaeffel
PSPerikles Simon
Perikles Simon
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
Purpose. It has been found in the chicken that the amount of retinal glucagon mRNA increases during treatment with positive lenses. Pharmacological studies support the idea that glucagon may act as a stop signal for visually induced eye growth. To gain more insight into the functional role of glucagon, the changes of glucagon and glucagon receptor mRNA concentrations in retina and choroid over time were studied. Furthermore, the abundance of glucagon and the glucagon receptor was studied in different fundal layers (retina, retinal pigment epithelium[RPE], choroid) and the blood. methods. Semiquantitative real-time RT-PCR was used to measure glucagon and glucagon receptor mRNA levels in retina and choroid after positive and negative lens treatment for 2, 6, or 24 hours, by unilateral −7- or +7-D lenses. Contralateral eyes served as the control, and completely untreated animals provided further reference data. Intravitreal colchicine injections (which are known to reduce the number of glucagon cells sharply) were used to verify that the related decline in glucagon mRNA could be measured by real-time RT-PCR. results. In the retina, treatment with −7-D lenses induced an initial upregulation of glucagon mRNA in both eyes, followed by a significant downregulation. The treatment with +7-D lenses showed a significant but transient downregulation in the control eye superimposed on a trend toward upregulation in the treated eye. However, the changes in glucagon mRNA expression were not confined to the lens-treated eyes but were also found, although sometimes to a lesser extent, in the non–lens-covered fellow eyes. There was evidence of a transient increase in glucagon receptor mRNA levels in lens-treated eyes after either −7- or +7-D lens wear. In the choroid, no effect of imposed defocus was detected. The injection of colchicine led to the destruction of approximately 75% of the glucagon amacrine cells but the mRNA level of retinal glucagon decreased by only approximately 50%. Glucagon receptor expression was found to be higher in the RPE than the retina and choroid whereas, in the blood, glucagon and glucagon receptor mRNA expression was below detection level. conclusions. The observed bidirectional regulation of glucagon mRNA in correlation with the sign of imposed defocus supports the idea that glucagon may act as a stop-and-go signal for eye growth. This is in line with a previous proposal based on studies of changes of the glucagon peptide content.

1 December 2020 in iScience
Verified
Journal Article
Open access
CBChristine Bus
Christine Bus
LZLaimdota Zizmare
Laimdota Zizmare
MFMarita Pauline Feldkaemper
Marita Pauline Feldkaemper
SGSven Geisler
Sven Geisler
MZMaria Zarani
Maria Zarani
JFJulia C Fitzgerald
Julia C Fitzgerald
PINK1 loss-of-function mutations cause early onset Parkinson disease. PINK1-Parkin mediated mitophagy has been well studied, but the relevance of the endogenous process in the brain is debated.